Pediatrix Medical Group (NYSE:MD) Price Target Raised to $18.50

Pediatrix Medical Group (NYSE:MD) had its price objective increased by UBS Group from $16.50 to $18.50 in a report published on Friday morning,Benzinga reports. UBS Group currently has a neutral rating on the stock.

A number of other brokerages have also recently commented on MD. StockNews.com raised shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research note on Wednesday, January 22nd. Jefferies Financial Group boosted their target price on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Mizuho upped their target price on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a report on Tuesday, November 19th. Finally, Macquarie initiated coverage on shares of Pediatrix Medical Group in a report on Monday, December 16th. They issued an “outperform” rating and a $18.00 price target for the company. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $17.08.

Pediatrix Medical Group Trading Down 9.6 %

Pediatrix Medical Group stock opened at $15.57 on Friday. Pediatrix Medical Group has a 12-month low of $6.62 and a 12-month high of $17.67. The firm has a market capitalization of $1.34 billion, a price-to-earnings ratio of -12.97, a P/E/G ratio of 1.74 and a beta of 1.57. The firm has a 50 day moving average of $13.89 and a 200 day moving average of $13.01. The company has a current ratio of 1.60, a quick ratio of 1.42 and a debt-to-equity ratio of 0.81.

Pediatrix Medical Group (NYSE:MD) last released its earnings results on Thursday, February 20th. The company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.12. Pediatrix Medical Group had a negative net margin of 4.92% and a positive return on equity of 15.47%. The company had revenue of $502.36 million for the quarter, compared to analysts’ expectations of $486.22 million. As a group, research analysts predict that Pediatrix Medical Group will post 1.38 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of MD. Pacer Advisors Inc. acquired a new stake in Pediatrix Medical Group during the 4th quarter valued at approximately $35,492,000. American Century Companies Inc. boosted its position in Pediatrix Medical Group by 628.2% during the fourth quarter. American Century Companies Inc. now owns 1,739,323 shares of the company’s stock worth $22,820,000 after purchasing an additional 1,500,485 shares in the last quarter. Oberweis Asset Management Inc. purchased a new stake in shares of Pediatrix Medical Group in the fourth quarter valued at approximately $6,122,000. Renaissance Technologies LLC grew its stake in Pediatrix Medical Group by 117.4% in the 4th quarter. Renaissance Technologies LLC now owns 838,800 shares of the company’s stock valued at $11,005,000 after acquiring an additional 453,000 shares during the period. Finally, Boston Partners boosted its holdings in Pediatrix Medical Group by 25.2% in the 4th quarter. Boston Partners now owns 1,956,353 shares of the company’s stock worth $25,922,000 after buying an additional 393,600 shares during the last quarter. Institutional investors and hedge funds own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.